PULSE BIOSCIENCES, INC. 8-K

What Happened
Pulse Biosciences, Inc. (PLSE) filed an 8-K on February 27, 2026 (Item 5.02) reporting that Kevin P. Danahy, the Company’s Chief Commercial Officer, gave notice of his immediate resignation effective that same date. The company stated the resignation was not due to any disagreement with Pulse on operations, policies, practices, or accounting matters. The filing notes Mr. Danahy played a key role in senior management and the company’s early commercialization efforts.

Key Details

• Resignation date: February 27, 2026 (effective immediately).
• Executive: Kevin P. Danahy, Chief Commercial Officer (CCO).
• Company statement: Resignation was not due to any disagreement with the Company on operations, policies, practices, or accounting.
• Filing reference: Form 8-K, Item 5.02 (exhibit: Inline XBRL cover page noted).

Why It Matters
An unexpected departure of a senior commercial executive can affect ongoing commercialization and go-to-market initiatives; Mr. Danahy was identified as important to the company’s early commercial efforts. For investors, the filing confirms there are no reported disputes with management or accounting, which reduces immediate governance concerns. Monitor subsequent company communications for information about an interim or permanent replacement and any potential impact on commercialization timelines or commercial performance.